Clinical Trial: Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers

U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT03139370) titled 'Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers' on April 26, 2017.

Brief Summary: The primary objectives of Phase 1A are to evaluate the safety of KITE-718, determine a recommended Phase 1B dose, and to evaluate the efficacy of KITE-718 in Phase 1B.

Study Type: Interventional

Condition: Solid Tumor

Intervention: * Drug: KITE-718

A single infusion of autologous genetically modified MAGE-A3/A6 T-cell receptor (TCR) transduced autologous T cells (KITE-718).

* Drug: Cyclophosphamide

Administered intravenously

* Drug: Fludarabine

Administered...